IMGN - Earnings call transcript Q1 2021

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning, and welcome to the ImmunoGen's First Quarter of 2021 Financial and Operating Results Conference Call. Today's conference is being recorded. At this time, I'd like to turn the call over to Courtney O'Konek, Senior Director of Corporate Communications and Investor Relations. Ma'am, please go ahead.

Courtney O'Konek

Good morning, and thank you for joining today's call. a progress that financial in issued of a results. we recent our first today, press includes release summary Earlier quarter XXXX be at immunogen.com. This this & a and section found can Media website press Investors under our recording of the release call of Medical are Chief and me Berkenblit, today and Anna our Enyedy, Mark With Susan President Altschuller, our CEO; our Officer; CFO.

months, upcoming will the business last three During events. for over anticipated and accomplishments today's our review call, results key we financial the

forward-looking uncertainties statements, SEC materially ImmunoGen use our an During actual Descriptions turn differ the will in filings. discussion, in may and from I'll that, of the results we our investment with included are the associated call statements. And Mark. such over risks and with to

Mark Enyedy

in morning, today. which and the joining SORAYA, program, projected from of primary the the fourth COVID-related everyone, some on the the of our lead for quarter color which the for you study third top XXXX. I'll into confirmatory quarter first moment. disease, submission line provide has more single-arm We pivotal third with this And in Good and recently enrollment now year our us a mirvetuximab. correspondingly trial timelines of second endpoint thank the platinum-resistant is shifted around Thanks, quarter completed in timing the impact to MIRASOL the and begin move Courtney. readout will accrual to anticipated data experienced also on our BLA expect the the XXXX. I We've into some of from updated of

full of accelerated to continue we mirvetuximab studies, potential these from results XXXX. positive in and XXXX in with approval approval Importantly, anticipate

in in of disease treatment half our of later protocol single-arm displacing study submitted approach expands recurrent patient of this chemotherapy anticipate to this cohort ovarian for initiating second platinum-resistant mirvetuximab cancer, we This ovarian lines year. further the cancer. for enrollment a study single-agent platinum-sensitive in Beyond and a in monotherapy

avastin with We accepted Phase an combinations. mature disease doublet patients in that data were pleased to plus year. in oral from ASCO to our were II platinum-agnostic this FORWARD mirvetuximab Xb Turning mirvetuximab at learn presentation for of

XX-patient carboplatin in Dr. neoadjuvant IST the under at setting. Arend mirvetuximab with combination way, now led a addition, evaluating in In Rebecca UAB by is

Finally, combined in randomized patients Germany in with standard-of-care study in comparing Philip enrollment a we're carboplatin the by a the to AGO this Harter supporting expected platinum-sensitive with IST mirvetuximab second year. recurrent led with of in half start large in to patient disease

Having full of advance in progressing to top I continue generate second malignancies. approval IMGNXXX next path in XXXX the a program, to potential hematologic with first BPDCN, our half We we in to expect patients CDXXX and approval expansion established pivotal data are frontline year. positive cohort in line Phase our

azacitidine refractory advancing data combinations from and with December. combination also frontline forward patients are look and studies in these in at in in and relapsed XXX AML We venetoclax to presenting ASH

we earlier-stage We our MacroGenics. our for ADAMX preclinical AACR at codeveloping targeting data to Moving with ADC, which IMGCXXX, presented pipeline. are first-in-class

Anna? that, of and provide to expect transformative over to Anna call And folate two ADCs activities to our as progress for years solid XXXX ADC, the clinical of generate products critical programs. and with XXXX and We and by you innovative alpha we evolution are IND-enabling tumors continued ImmunoGen's also next-generation market we commercialization. an submit to additional I'll targeting our color We our IMGNXXX prepare for and apprised on bring to as application further prepare the for turn hematologic look data forward malignancies. our receptor keeping some clinical year-end. portfolio to in

Anna Berkenblit

SORAYA. with Thanks Mark. start I'll

trials which, well variable factors six-week a study, effect tapering as accrual in including delay, to shifted submission fourth XXXX. the first has due a moved the net in the in mentioned, weeks experience factors, our to recently COVID-XX enrolled this relative MIRASOL While fully also to for Despite as earlier reporting combination timing they activation These affected patient Mark the some has roughly of had enrollment. for anticipated of prior imminent site of SORAYA BLA as the completion and we top recent into was line COVID-XX contributed have more screening planned an trial. start, quarter The has quarter. as our also accrual data of having into activity

planned submission in BLA While the the part expect of we latter approval of MIRASOL to new the by living ovarian in of a the third forward and XXXX XXXX, line we and quarter data initially highest full expected now supplemental opportunity the business, for look the are for the the therapeutic end of SORAYA top first top offer patients studies of with to line we option XXXX. priority to with half cancer. data Completing the the

half This pursuing initiation we To studies enable ovarian of are in activities year. into setting, are combination the The the study of setting. as increasing setting upfront there is needed. first in a mirvetuximab for frontline an and under based platinum-sensitive for continued patients lines for opportunity submitted this trial PARP University carboplatin. cancer initial is we assess patients ovarian we with population. population the With with Operational Arend. this non-platinum regimen in the a a the trial Rebecca is of expand encouraging, to second therefore, Alabama investigator-sponsored now uptake way of have single-arm data of recurrent under and of earlier whom way in are maintenance to inhibitors monotherapy protocol platinum-sensitive treatment, An cancer to is the the in in pretreated heavily have, mirvetuximab the Dr. our neoadjuvant at FDA

our at of support diagnosis folate alpha as of incorporating will testing trial part standard-of-care. this goal receptor Importantly,

combination Dr. of recurrent trial, in the addition study carboplatin with is a start we disease this to to standard-of-care in the half second This in trial Harter In supporting in with year. to are randomized comparing platinum-sensitive Phillip mirvetuximab Germany. also slated

mature at have our the mirvetuximab starting will from combination in trials to closer oral Xb a addition mirvetuximab efficacy plus FORWARD of we agent in lines pleased and of cancer from achieving in believe to in establishing June. cohort University us data of of we its ovarian Dr. platinum to ASCO supporting step avastin regardless for Phase II in a will are the cohort ovarian O'Malley cancer bring avastin, use Ohio therapy. plus Dave from presentation present these combination In our safety our new State recurrent mature selected virtual data carboplatin, as which earlier status with goal mirvetuximab of choice and

city cohort our folate gemcitabine for in accepted from HOPE were posters at from from ASCO. evaluating mirvetuximab with of patients trial with two the addition, presentation Data in combination collaborators an In with poster expansion receptor in advanced and alpha in evaluating Farber, positive in microsatellite combination a cancer recurrent progress or stable platinum-resistant with cancer. patients mirvetuximab pembrolizumab Dana endometrial ovarian trial from

ADC. IMGCXXX, our targeted to ADAMX Moving

observed MacroGenics disintegrate in known but matrix presented solid anti-ADAMX for are the we metalloproteinase April, member because tissue normal overexpressed of human PDX antibodies models, as PDX and development, triple-negative degraded solid on cell IMGCXXX xenograft tumors partners in ADC ADAMX, clinically at evaluated and non-small that models activity efficiently a tumors. in minimally patient-derived multiple attractive in AACR in including against pancreatic lung, of an expression solid demonstrated lines. cell similar Our data At to of tumor IMGCXXX family target expressed in breast, ADAMX with cancers. the and tumors or broad identified it activity is panel gastric compelling expression by internalized ADAMX and relevant a

potential excited study ADAMX escalation a and collecting actively to for known Phase the I about tissue enrolling patients dose immunohistochemistry. expression express are to our We're We at in in XXXX. Susan? with Susan medical retrospective look ADAMX solid to cover the by tumors program, tumor assessment we financials. a of With forward over to presenting I'll early and that, turn call this meeting data major likely

Susan Altschuller

Anna. Thanks

the expenses For $XX.X the from was XXXX, generated nearly $XX.X compared all MIRASOL the noncash We fees revenues. research IMGCXXX for costs. SORAYA, first $XXX.X the and XXXX. quarter with million million ended costs compared due development with of $XX.X cash. clinical came in quarter of greater to million, quarter of This advancing of million royalty to expenses Operating million year-over-year personnel first million million greater revenue, primarily for studies of $XX.X quarter due XXXX, professional development external and were to first first expenses $X.X costs. manufacturing to in related comprised we and $XX.X G&A and increased were increase our of which

Our financial guidance for XXXX remains unchanged.

equivalents million million cash We between $XX expect between million, to $XXX and million year-end be be and and at operating revenues million. to million between and be $XX cash and to expenses $XXX $XXX $XXX

cash the questions. with the operations expect fund We is that, to We ahead XXXX. to forward open what current look of half second call our of And us. to I'll into

Operator

Cannacord. of [Operator first Instructions] John Newman question from comes Your

open. now is line Your

John Newman

Thanks thanks question. for all the updates taking my for and

looks that allow line So when SORAYA now surface Thanks. to might it like that the detail will fourth responses you durability Mark, the data the I line in wondered regarding 'XX, the little just present quarter a of data? top of for top bit us more give you

Mark Enyedy

to ask I'll And is comment but further, Anna any Yes. answer the yes.

Anna Berkenblit

right, John. Yes, that's exactly

pace not reasonable data will course of line response. over few Given study, enrollment a of only the of months, of the the top we we'll including entire also for that but primary ORR endpoint, have the anticipate duration we estimate the last have

John Newman

different topic. question on I one a then just had follow-up And sort of

regarding So with there's accelerated FDA been a recently lot of activity the approval.

companies - of have just agency that comfortable. up got as the already significant that comment time your more the I approval positive. running is if is seems It views you've there. a studies would studies your you could accelerated on actually running, confirmatory already understanding thoughts study at if like that and be confirmatory the Our agency wondered

how Just Thanks. about you think to curious that. as

Mark Enyedy

guidance. Yes. at in the I high fact, regulatory mean, that's, Maybe level, a just

completed about So your is, when study, time thing but say first the you you want of study great, the regulatory to talk make in to sure accelerated enrollment the to you've at action. FDA they confirmatory approval we an

formal provide every guidance applicant. that's that they So

that So everybody what not in is practice achieves that happens objective.

We sit overall in some the on were saw disposition very right place. expect we of which these to to ODAC of relative of the ODAC through. hanging I to And had so. accelerated you with approvals, Anna then And think the that some approvals, the pleased the be so-called opportunity

Operator

of is open. now comes Your your Schmidt Mr. line Sir, Michael next Guggenheim. from question

Michael Schmidt

comments PARP and pretreated related wondering just taking a how about your question had for think in on And both in more MIRASOL. the with SORAYA might use I heavily perhaps to specifically? years, increased inhibitors mirvetuximab recent questions. patient ongoing population you of inhibitors perform Thanks PARP my studies, a

Anna Berkenblit

Michael. Sure,

years, we've And prior are a what we've we the maintenance being to if inhibitor there past expect have percentage I And over And seen, is used for each absolutely regardless receiving enrolled impairs each increasing activity payload and PARPs sense PARP. is sensitive given platinum looked six prior reason our it no So, or makes with therapy. you PARP maintenance cross-resistance that not. can between repair which incorporated really of the PARP of study, recurrent across into ability an trial kind a biologically, frontline damage. and that mirvetuximab DNA patients tell has nice that tubulin-directed to any

Michael Schmidt

a then sensitive And study sense. in platinum recurrent your Makes new question patients. on single-arm

you size if of of wondering the commercial potential the outline study relative help perhaps size the sort could Just us the population. also opportunity maybe SORAYA just patient of and to the timelines

Anna Berkenblit

Yes.

still therapies. agent to platinum-sensitive So, than greater unmet a really recurring they and of platinum-sensitive their of increasing an to for the larger we after disease at recurrent but this population they're last little platinum, high bit that increasing patients single definition risk bone an tired of reactions sensitive are arbitrary they're with months later-line may other a mirvetuximab we've or be need allergic designed address dose six disease by with in know platinum really need the who study active rather well-tolerated patients technically address marrow

nice. we platinum-sensitive cohort the And with mirvetuximab well, So we those the cohort actually and had of way a had that look enrolled of patients biopsy four to - handful patients, - we in I had indeed who when a looks then our of disease. couple Phase of - study three activity at we therapy from the than quite patients cohorts, prior lines back, our more

that And so, the have we study to we've just submitted the has just supported that protocol - FDA.

two-stage a you as study. If can it think of basically design

we And to ready the study, once share more open so are details. we'll

Mark Enyedy

an patients. our that folks X,XXX tell only a the Michael, of platinum-sensitive terms it's the are subset evolving market third-line of data targeting of about opportunity, DRG in patients us Obviously, segment we're those but just marketplace.

the platinum-based all see won't and are setting with data depend, X,XXX generate those patients there degree, combinations actually of both efficacy a little well. tolerability large important what you So, we degree, terms what can effectively equally on there that the it efficacy relative to to of to get and, that some seen will in and a we we've on in compete think But based bit but scarce. quite as we preliminarily, convenience monotherapy

Michael Schmidt

I to evolving about new earlier-stage few speak then company-sponsored did I speak thinking could potentially in you investigator-sponsored was patients. And supporting perhaps wondering studies if just a know studies. you about

Mark Enyedy

Sure.

So, mentioned, able for reasons by really patients. to described. in Arend in we're tissue neoadjuvant UAB levels to access having - the as this setting, Dr. alpha being tumor Anna folate receptor study about of frontline assess that the being and out conducted essentially being One, excited led she fresh such those

XXX and then, we're the excited is that. So, this study Philip upwards Harder patients. controlled of about AGO we're And randomized I with think a study doing of

direct strong care. the a have to comparison of expect we against terms signal there of in standard So, pretty

are effort setting as in we that speak. details working of company-sponsored design And and so, the the we evaluating through

Operator

question is Sir, from Peaker comes your next open. Your Cowen. of Boris line

Boris Peaker

just probe patients just the I new so understand you the SORAYA delay patients’ trying all already be the kind terms SORAYA to in for the in to since trial of of initially wanted the how maybe diagnosis, system? relying cancer. ovarian on I'm COVID in impacting diagnosed aren't shouldn't is study

Mark Enyedy

in of Yes. in that XX% you Anna which color. working quarter a little in us first what as rates with let comparison CRO. year we're accrual include more is cancer saw they IQVIA to their decline But a in QX last of start the I’ll more with, ovarian our of other to they this And give studies, tell year. studies than

So, some what as Part of impact. is there variability. was well a COVID we’ve seen there's

a should particular the be number variability seen during what study of some So, accruals in with direct the we active early and we’re acute normally which - between we we're correlation to accustomed in that the have COVID. in and it of sites to sort throughout seeing accrual was our spring we've CRO

Boris Peaker

my guess be study you considered to I do on interesting. BPDCN. that in need what It’s second us it again is to show Remind successful? question for

Anna Berkenblit

Yes.

who therapy the BPDCN to are full And with that So, is will frontline or not that frontline These had any the radiation approval patients to may patients. systemic XX include we've have enrolling. FDA have it local cohort surgery support up therapy. aligned had

of a XX%. CR/CRC so or rule CR And to the study clinical is designed out rate

Operator

Your William Hsieh from Andy next question of comes Blair.

now open. Your line is

Mark Enyedy

go Operator, there? you are Andy, probably next the question. I think we’ll to

Operator

Hello. Andy?

Mark Enyedy

we Well, next take question. the

Operator

right. All

Jessica Fye JPMorgan. from of comes question Next

Mark Enyedy

Jess? missing the like Operator, can Because you here? communications check seems it we're two people already.

Operator

Yes.

a me Hello, sir. here, Just give second Ms. Jessica.

is line Your open. now

Luke Brennan

guys you hear Can Hello. me?

Mark Enyedy

like Andy. Sounds that’s

Luke Brennan

Sorry.

is Sorry. This on is Brennan for Jess. this Luke

Mark Enyedy

Oh, great.

Luke. Okay. Hi, Good.

Luke Brennan

Okay. Thank morning. for the question this

approval? on So, single-arm guys FDA sign the later-line goal on for as to expect in basis patients platinum FDA that with sensitive feedback is protocol, the you the off that the for the trial

Anna Berkenblit

No.

to So, There's start basically, when FDA. getting period. protocol we ready submit a we are study, XX-day the waiting to a

that feedback, patient it if we'll have the actually chance so waiting, we opportunity of a incorporate in We, are that from do before there's we they to enroll good study. hear the so, not first FDA. this And anything course back may have

Luke Brennan

so, - both monotherapy I bit guys give a the trials same dynamic the guess more the between little you color setting? therapy I the could and on starting combo guess in

Anna Berkenblit

the monotherapy in with So more is for or platinum. study lines prior two patients

So, with at two. least

platinum-sensitive And population three a platinum So, but that again therapy. is technically lines prior two to that else. something still really is of needs

planning but prior also a who line who further are reaction that of would to one them hypersensitivity We had platinum. for patients inappropriate therapy allow make had platinum-based

later there increasing in think we setting, platinum-sensitive that just So patients is because are more we'll frequency with again, disease. line a be

setting, is upfront. one so that's the combinations, neoadjuvant carboplatin Our

to the appropriate each basically IST be about then being in patient. doublets very first study mentioned study be We're in randomized randomized those carboplatin are patients any that our II that, therapy had Mark to of for versus And And opportunity standard-of-care done going standard, not as patients. excited have who mirvetuximab study, mirvetuximab will that's plus a untreated with platinum-based Germany, maintenance because that therapy so before. Phase the

Operator

next open. Hsieh Andy now of your Blair. Your Sir, is comes from William question line

Andy Hsieh

for my question. Thanks taking

for enrollment on opportunities. also, this you little and back potentially might that you're but serving I study compendia the to And of as early of relative Mark, if SORAYA be I'm congratulations technical a have platinum-agnostic question, educate that confirmatory of label kind opportunity? do review new kind I'm can forth of process. you the interaction on foresee that you might how questions trial completion. just two wondering much curious listing regular FDA regarding bit process. the the a the answer kind MIRASOL have expansion us just proposing, about It difficulty, the Sorry and to

Anna Berkenblit

Yes.

start. So I'll

the So platinum-sensitive, platinum. platinum-agnostic, months disease, it's of monotherapy These exactly patients later the start still that in than this technically patients options. non-platinum Again, we recurrent need who greater getting ready are other to year six mirv recurred last new of having based are study are not platinum-sensitive these Andy. than dose

So going this to later year. is get that study slated

that Moving plus a example now compendia think bevacizumab. completing think you we're data will out mirvetuximab that. two unlikely compendia support us with that start studies listing. this confirmatory I would to I listing. likely is as study to read for it's to serve Typically, later year planning MIRASOL to our the separate right best combination for the need study And us prior MIRASOL

have You population agnostic, may of at That presented disease couple with is so XX again, our anticipate cancer. we And And specifically cohort ovarian cohort, platinum another have will well gain also that second of patients. recall, generate carboplatin may twice. a based doublet, formal data we now, expansion support ago cohorts from we a that with cohort compendia broader efficacy the very a and in planning ASCO one we could years in was recurrent platinum-resistant that patients in that registration those on the case a compendia safety trial. plus for listing separate we're advance of to be from label listing. two mirvetuximab the data then It

Andy Hsieh

just And the then Anna, in about context question, trial. curious MERV clinical of your curve I'm thoughts using investigators last and learning on a

recruiting if I'm are in you had benefit wondering I SORAYA that of and just efficacy expect sites So specifically, for some see to participated concurrently from FORWARD and clinical sort safety MIRASOL? or patients

Anna Berkenblit

Yes.

Phase from FORWARD have recall of and the me gives data of you So study, we I, or And from went of mirvetuximab III sites were a for I over it who FORWARD profile in Andy, I XXX mirvetuximab study. the XXX Because with with to we the FORWARD quite a safety dosed XX Phase lot good. wealth sites comfort. I in patients may XX looked

SORAYA MIRASOL the investigators expect bellwether important there patients different well was that are were completed you're ensuring that tells MIRASOL think absolutely best on I and from new FORWARD strategy me, that and would I, XXX sites I I really informed of the did terms to manage integrity. in We of in vision, discontinued focus those that no new data is SORAYA patients blurred have I studies. only educated. a that be and right. for optimal to sites, and and on mirvetuximab, the due and really in to like SORAYA, both say, We and that included one For appropriately you in accrual picked we we FORWARD in will very getting us,

Operator

Ramakanth Swayampakula question from H.C. from Wainwright. Your next comes

open. now line is Your

Swayampakula Ramakanth

with of two H.C. the full as SORAYA from in the This you're approval with evergreen Wainwright. Mark, program. and questions. being studies, also various tested quick is accelerated the to regimens mirvetuximab for MIRASOL regulatory couple for FORWARD RK embark A approval, combination trying strategy you

and behind put you it's And in resources yet bold some of approval the when indication? step comfort think no lot this gives with a molecule any big so, to what confidence could a

Mark Enyedy

thing a accelerated in the looking for first approval mirvetuximab XXXX. the is at So we the relatively quarter time of line with are first submission BLA

I which review relatively approval. expect We could short product, a have for reasonably fast us review, and track and window designation for priority gives this think we

as as objective widely Our mirvetuximab is data that be then warrant. to used ensure the can

be approval. is on we to compendia placed us at that time available listings some the could And of initial so, this why the emphasis

consistent be the so in and of available their that the as compendia penetration use goal would the that. listing with them to mirv really accelerate label that's here barrier a And to within its not product is physicians decide then reimbursement to own so both to discretion

don't we've in generated. strategy, So particularly don't data light I as of that we high-risk - that the view already a

of generating look further So in benchmarks. really response rates needed that there's no data compelling in earlier some the Phase work, And combination actual than to-date, that quite at generated the to mirv these in some other looked publications relative line terms the I from avastin. of we've generated with and we our work data of current particularly patients the from we've when then

from but months. And initial with a progression-free rate of our was XX% high so response is an data expression in remember you carbo end, may patients and XX - survival levels it's small

If common our ESMO, at response look rates. - were high at very published you similarly, our triplets that

our to are goals here really so lever And that.

XXXX. combination of So carbo the of it's approval be in we just conviction I availability an I our accelerate and work, initial and a drug responsibility this that's think about the this mean should drug both have avastin of part by overall to lot choice and driven for And conviction of that agent our that

Swayampakula Ramakanth

AML. could you. is drug also Perfect. this multiple on IMGNXXX, BPDCN followed Thank initial while focus certainly by target tumors, On your liquid

should What on So do the profile you that? with of liquid what your you're in do plans to would XXX following we trying be - expect tumors? broadening or additional

Mark Enyedy

Right.

a with designation mirvetuximab. the that in mean therapy can FDA foray in interesting But goal expressed recall pursuing pursuing we approval in in yes, our speak. we range strategies In as of we the case patients, Initially, an with got And of around studies full frontline for program So monotherapy, use I where of been but we'll with that and the additional and hematologic align our may terms in we are venetoclax. But the clearly, high which relapsed/refractory malignancies. case myeloid XXX there is across BPDCN, cohort combination azacitidine portfolio, of principal leukemia. has single-arm we have is is to our has that support set some as benchmark approval. CDXXX you breakthrough acute disease fast-to-market in to ethos development level our - and of activity, where saw been accelerated

that doublet the at doublet create generate most to rates so, that a we expect to regimen competitive. make a of looking that was We're that significant and - the would working into both data to I with speak, and beyond and potential see And year we goal have the BPDCN ASH at can duration through represents to the importantly, as integrate yes, response at the that of end But we XXX think, label. expansion response triplet triplet. whether

Operator

of question next from Kennen Capital MacKay Your comes RBC Markets.

line now open. Your is

KennenMacKay

for the difficulty] taking question. Thanks [technical

Mark Enyedy

Kennen, every make only third you're substantially. about couldn't out I up I - word. breaking

Kennen MacKay

[technical difficulty]

Mark Enyedy

get not did I apologies. that, Kennen,

follow-up So maybe off-line. can we

Sorry, yes. go the Operator, question. to next

Operator

comes question Catanzaro of from Joe Next Piper Sandler.

is Your open. line now

Joe Catanzaro

patients. single-arm me Thanks follow-up in on so the quick monotherapy one Maybe for platinum-sensitive much just trial question. one for taking to my

experience, levels So Anna, and Phase what enrolled exactly you receptor utilized folate maybe I patients. on that you various it And could a trial? had bit specifically, little expression you I you elaborate saw way actually how mentioned platinum-sensitive if relates that to the you in Thanks. had that the cutoffs more in back back Phase wondering those in I'm patients.

Anna Berkenblit

Joe. Sure, Yes.

status. treatment eye the platinum day prior accelerated therapy of mentioned, of which I patients had had drop with to regardless And cohort platinum prior. biopsy initially in cohort, four three the was in silent That lines patients was olaparib four what status. affectionately with as three to approval as on when its got called we So back the in we we've also

following So of that sort model. we were

focus the enroll did with enough were I a very our cohorts - result, of not two high disease, to though later-line those lines that we patients patients FR platinum-sensitive and with was intent nice mean, prior alpha three at very patients across had the response. a had therapy even nice a time As really on these disease.

that single-arm we design we're this we're our that have to data the study later support the So with these get that data experience. I are is using from very internal the to on-track that pleased Phase year. of open And

basically to And and study - and actual the more once so design a And is it's again, going sort of design. up specifics we about the have can talk we're two-stage timelines. running,

Operator

Shi comes question from Kelly of Jefferies. Next

Your line is now open.

Kelly Shi

have one your phase of I one early trials. from question

going So to the also, I'm do you the there you. screen ADAM-targeting diagnostic for showed the proof-of-concept at ongoing after dose treatment a at nice wondering, XXX, also, on Thank patients is think are recently efficacy And based there any predictive you data you ADAM-targeting ADAMX biology? ADC, previous been Is And escalation ImmunoGen? antibodies, has any? are from phase? what if development lastly, learning companion AACR.

Anna Berkenblit

Sure.

approaches matrix for is patients. the invasion. prevent that out ADAMX MMPs, to And were disintegrant mechanistically really cancer a so we metalloproteinase metalloproteinase, member well of family. turn the and try remember oriented targeting matrix So didn't I certainly days to metastasis and And those

we're is using ZIP toxic payload very target cells and - tumor code maytansinoid to our potent as to really normal spare ADAMX next-generation tissue. it a However, to

rationale, wouldn't it targeting think really of as it's mechanistic - not to tumor our payload toxic but I So really biological cells. more the a

around question inform your or we now data not. to select are of Phase I dose or in whether we screening, terms for escalation patients to need will generating next In ADAMX expression not

antibody because ADC. collaboratively, your that As you and and target doing of select tumors. to ADAMX broad of saw if CDX we're a needed. right to to poster, patients if around to their in us ADAMX reasonably actually prior learnings speak this validated a a from across poised then now, a can't developed the AACR cutoff is novel needed. all our expressed this question we've be get ADAMX to by target. targeted And And we spadework a will develop point MacroGenics the really highly last with that But antibodies, us brought cutoff, is and range expression I

escalation we're Phase is really early So sharing trial I excited. enrolling, forward look dose to and in we The data XXXX.

Kelly Shi

what Thank platinum-agnostic receptor in you is the the just for lasting information. for ORR ASCO have in another and patient regarding this Thank the what Or should way, high update population? quick very be wonder upcoming population? ask, late I by very the another the in patients. benchmark mirv achieved full It's question should combo I much. standard-of-care estimated also selective I you. PFS alpha this

Anna Berkenblit

Yes.

know a So In you there been there have you tell recurrent And potentially studies or looking look disease from FORWARD I platinum-resistant poor with at our you XX% at I unselected XXXX, avastin a design there's retrospective, patients alpha patients which is alpha chemotherapy, confirmed is of high two patients, But how the prognostic rate populations, but be in you'll a did. factor. X.X you AURELIA, would for anything platinum-resistant not plus I published, so worse AURELIA median don't at upper high can receptor certainly exploratory overall to study FR ESMO that FR standard-of-care. use something to do mostly I and what to not at are analyses would that see may population a than that the will: if months. if separate point assess response study They had folate that would looked I in alpha and PFS platinum-sensitive. did the XX% alpha assuming

prior looking for in to one you there therapy, GOG between the is OCEAN somewhere PFS X.X months. is rate Moving and to the at XX.X would and the point with line disease, mid-XXs XXX study, of and recurrent platinum-sensitive and response study doublets I the the platinum-based patients

mature our from cohort an will mirv back you the when at ASCO. at our in data be oral presentation mind that that keep your Dr. presenting of So O'Malley see

Operator

for like call final would over hand our I presenters comments. the back go to Presenters, Now please their ahead. to

Mark Enyedy

you particular, apprised we the forward Thanks. year. and for And Well, or of anyway our appreciate this least at seeing you data morning. to the in Zoom progress updates on your look you. Thank there. We time and product keeping ASCO in

Operator

today's all conference concludes This you joining. call. Thank for

You may disconnect. now

Immunogen (IMGN) 10 May 212021 Q1 Earnings call transcript